Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPAC IV: Moxifloxacin vs Placebo for Uncomplicated Appendicitis
NCT06210269Not yet recruiting
- Sponsor
- Turku University Hospital
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of moxifloxacin in acute appendicitis (2 arms), sponsored by Turku University Hospital. Primary endpoint: Treatment success at 30 days. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
moxifloxacin
03
Conditions
acute appendicitis
Beyond the preview
Go deeper on NCT06210269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06210269.